<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2049">
  <stage>Registered</stage>
  <submitdate>14/07/2008</submitdate>
  <approvaldate>14/07/2008</approvaldate>
  <nctid>NCT00716534</nctid>
  <trial_identification>
    <studytitle>Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)</studytitle>
    <scientifictitle>A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2007-007107-32</secondaryid>
    <secondaryid>M10-301</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced or Metastatic Non-Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-869
Treatment: drugs - Placebo for ABT-869
Treatment: drugs - ABT-869
Treatment: drugs - Carboplatin
Treatment: drugs - Paclitaxel

Experimental: A - 12.5 mg ABT-869 + Carboplatin/Paclitaxel

Experimental: B - 7.5 mg ABT-869 + Carboplatin/Paclitaxel

Placebo Comparator: C - Placebo (7.5 mg or 12.5 mg) + Carboplatin/Paclitaxel


Treatment: drugs: ABT-869
12.5 mg ABT-869

Treatment: drugs: Placebo for ABT-869
Placebo Comparator (12.5 mg or 7.5 mg)

Treatment: drugs: ABT-869
7.5 mg ABT-869

Treatment: drugs: Carboplatin
Carboplatin (AUC 6 mg/mL/min)

Treatment: drugs: Paclitaxel
Paclitaxel (200 mg/m2)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>Disease Progression</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival, best response rate, time to tumor progression, objective response rate, best percent change in tumor size, duration of response</outcome>
      <timepoint>Disease Progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survival Rate</outcome>
      <timepoint>12 Months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject must be at least 18 years of age.

          -  Subject must have cytologically or histologically confirmed non-squamous NSCLC

          -  Subject must have recurrent or advanced (Stage IIIb with pleural or pericardial
             effusion) or metastatic (Stage IV) disease that is not amenable to surgical resection
             or radiation with curative intent.

          -  Subject has measurable disease, defined as at least 1 unidimensional measurable lesion
             on a computed tomography (CT) scan as defined by RECIST (for subjects in the
             randomized portion only).

          -  Subject has an ECOG Performance Score of 0-1.

          -  Willing to take adequate measures to prevent pregnancy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  The subject has NSCLC with a predominant squamous cell histology

          -  Subject has hypersensitivity to paclitaxel.

          -  Subject has received any anti-cancer therapy for treatment of NSCLC.

          -  Subject has received radiation therapy within 21 days of Study Day 1.

          -  Subject has had major surgery within 21 days.

          -  Subject has untreated brain or meningeal metastases.

          -  Subject is receiving therapeutic anticoagulation therapy.

          -  Subject has a central thoracic tumor lesion as defined by location within the hilar
             structures.

          -  Subject has proteinuria CTC Grade &gt; 1 at baseline.

          -  Subject has a history of, or currently exhibits clinically significant cancer related
             events of bleeding.

          -  The subject currently exhibits symptomatic or persistent, uncontrolled hypertension
             defined as diastolic blood pressure (BP) &gt; 90 mm Hg or systolic BP &gt; 140 mm Hg.

          -  The subject has a history of myocardial infarction, stroke or Transient Ischemic
             Attack (TIA) within 6 months of Study Day 1.

          -  The subject has a documented left ventricular (LV) ejection fraction &lt; 50%.

          -  The subject has known autoimmune disease with renal involvement (i.e., lupus).

          -  The subject is receiving combination anti-retroviral therapy for HIV.

          -  The subject has clinically significant uncontrolled condition(s).

          -  The subject has a history of another active cancer within the past 5 years.

          -  The subject has active ulcerative colitis, Crohn's disease, celiac disease or any
             other conditions that interfere with absorption.

          -  The subject has a medical condition, which in the opinion of the study investigator
             places them at an unacceptably high risk for toxicities.

          -  The subject is pregnant or breast feeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>145</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 19042 - Bedford Park</hospital>
    <hospital>Site Reference ID/Investigator# 23682 - Cairns</hospital>
    <hospital>Site Reference ID/Investigator# 21862 - Lismore</hospital>
    <hospital>Site Reference ID/Investigator# 19043 - Woodville South</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>4870 - Cairns</postcode>
    <postcode>2480 - Lismore</postcode>
    <postcode>5011 - Woodville South</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Jau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Santo Andre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kyjov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Nachod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pribram V</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kirov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie (prior sponsor, Abbott)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Genentech, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to determine the clinical efficacy and toxicity of ABT-869 in
      combination with carboplatin and paclitaxel in the treatment of subjects with advanced or
      metastatic NSCLC.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00716534</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Justin L. Ricker, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>